Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DFine rakes in $30m for spine surgical tech

This article was originally published in Clinica

Executive Summary

San Jose, California-based orthopaedic company DFine has secured $30m in series D financing, which it will use to expand commercialisation of its minimally-invasive spinal surgery technology. The financing was led by BBT Fund and Highland Capital Management. The company's StabiliT vertebral augmentation system is designed to treat vertebral compression fractions caused by osteoporosis or cancer. The system injects a bone cement, made from a proprietary energy-responsive polymethymethacrylate (PMMA) formulation, into the fractured vertebral column to stabilise the spine. The StabiliT is able to increase the viscosity of the cement by applying energy to the material. The system is commercially available in the US, and can be used only for clinical investigation in Europe.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel